AHCYL1 mediates the tumor-promoting effect of PREX2 in non-small cell lung carcinoma.

ABSTRACT: Rationale: As the most common form of lung cancer, non-small cell lung cancer (NSCLC) is still a challenging disease. Even though molecular-targeted drugs have greatly benefited NSCLC patients, the limited number of effective targets and the emergence of drug resistance necessitate further research to identify new candidates and improve clinical outcomes. Phosphatidylinositol-3,4,5-triphosphate-dependent RAC exchange factor-2 (PREX2) is highly expressed in multiple cancer types and poses high mutation frequency in lung cancer. However, the study of PREX2 in lung cancer, especially NSCLC, is few and unclear, thus, the role of PREX2 and the regulatory mechanism of PREX2 in NSCLC is worthy of further investigation. Methods: To determine the tumor-promoting effects of PREX2 in NS

SUBMITTER: Lei M 

PROVIDER: S-EPMC12068309 | biostudies-literature | 2025

REPOSITORIES: biostudies-literature